Region — US. Neutral scientific reference — not offered for sale here.
Explore /
DSIP (Delta Sleep-Inducing Peptide / Emideltide) Research reference — not for sale
DSIP (Delta Sleep-Inducing Peptide / Emideltide)
Peptide
also called — DSIP · Delta Sleep-Inducing Peptide · Emideltide (the name the FDA uses in the Federal Register) · nonapeptide · sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) · CAS 62568-57-4. INCI: none
sleep / circadian(also studied:) withdrawal, stress, pain — research context
Research / reference — not for sale, not approved. The honest crux here: the name is a claim the human evidence doesn't robustly support. ~50 years of study, mixed and contradictory results, and — remarkably — no known receptor or gene. No dosing published here.
In brief
DSIP (regulatory name Emideltide) is a naturally occurring nonapeptide named for its ability to promote delta (deep-sleep) EEG in rabbits. But despite roughly 50 years of study, the human evidence that it reliably induces sleep is limited, mixed and contradictory — the best-designed trial found only weak effects — its mechanism and even its receptor are unknown, and it is not approved anywhere. The name is more definitive than the data.
Legal standing, by region
European Union
Not approved
Not approved; not eligible for magistral/officinal compounding.
United States · your region
Not FDA-approved (503A Cat. 2)
Not FDA-approved. Placed in 503A Category 2 (Sept 2023); scheduled for PCAC review in July 2026 under the name Emideltide, covering proposed uses in opioid withdrawal, chronic insomnia and narcolepsy (docket FDA-2025-N-6895). A change in review status — not an approval.
International
Approved nowhere
Approved nowhere.
Evidence, by outcome
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Delta / slow-wave EEG (animal)
The original finding; animal, and even here later work was mixed
Monnier & Schoenenberger 1977 (rabbit) · Increased delta activity
CChronic insomnia (human)
Human evidence is limited and contradictory — the "sleep-inducing" name overpromises
Small 1980s studies (Schneider-Helmert) + Bes et al. 1992 · Mixed; some positive, but the strongest trial showed only weak effects
COpioid / alcohol withdrawal, stress, pain
Thin; not replicated to modern standards
Older, small studies · Suggestive
DMechanism / receptor
No confirmed receptor; gene not identified; possible bacterial origin
— · Unknown
—Safety
Long-term safety not established
No modern human safety RCT · Unknown
—Identity a naturally occurring nonapeptide (9 amino acids, ~849 Da; < 40 aa → peptide), amphiphilic, notable for crossing the blood-brain barrier and being unusually absorbed via the gut. Found in small amounts in brain, pituitary, gut, blood and breast milk. Unusually, it has no identified receptor, and the gene has not been found — a basic-biology gap that matters when reading the "mechanism." ## Development & history - Isolated in 1974 (characterised in PNAS 1977) by the Swiss group Guido Schoenenberger and Marcel Monnier at the University of Basel, from the cerebral venous blood of rabbits in an electrically-induced sleep state. Infused into other rabbits, the peptide increased delta-frequency (deep-sleep) EEG activity — which is exactly how it got its name.
- The mystery: decades later, no DSIP receptor or precursor gene has been identified in rabbits, and BLAST searches align the sequence with a hypothetical Amycolatopsis coloradensis protein — raising the possibility that DSIP may be of bacterial origin. In other words, the compound's fundamental biology is still unsettled. ## Mechanism (as proposed), and it is not approved anywhere. The name is more definitive than the data.
Sources — 4 cited
01Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram-(sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977; Monnier M, et al. (Original vs synthetic nonapeptide.) Experientia. 1977.
02Schneider-Helmert D, Schoenenberger GA. (Human sleep studies, 1980s.)
03Bes F, et al. (DSIP in chronic insomnia.) Neuropsychobiology. 1992.
04Wikipedia / primary literature on the absent receptor/gene and possible bacterial origin.
Review status
Not yet reviewed
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (US review status evolving — re-check the July PCAC/Emideltide outcome).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
Region — United States
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.